Transcatheter aortic-valve replacement for inoperable severe aortic stenosis.

By R. Makkar, G. Fontana, H. Jilaihawi, S. Kapadia, A. Pichard, P. Douglas, V. Thourani, V. Babaliaros, J. Webb, H. Herrmann and 15 more. New England Journal of Medicine, 2012

1,290 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/9cce98e0cc2f0de9ce46bd6bbd4a2f6b44da67af

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. (2014, background): “Transcatheter aortic valve replacement (TAVR) is an alternative to SAVR in selected patients with aortic stenosis (5,6).”
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, methodology): “ies and multicenter registries that include large numbers of high-risk patients of Aortic Transcatheter Valve) IA trial of a balloon-expandable valve (50,53), th at 30 days, 1 year, 2 years, and 5 years (p1⁄40.”
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, methodology): “ies and multicenter registries that include large numbers of high-risk patients of Aortic Transcatheter Valve) IA trial of a balloon-expandable valve (50,53), th at 30 days, 1 year, 2 years, and 5 years (p1⁄40.”